Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

NCT00019019 ↗

Phase 1 Completed 70 enrolled National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of carboxyamidotriazole and paclitaxel in treating patients with advanced solid tumors or refractory lymphomas.

Timeline

Start: 1994-10
Primary completion: 2006-07
Completion: 2006-07

Publications

Results Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin Cancer Res. 2001 Jun;7(6):1600-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paclitaxel	Small molecule	110 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	250 mg/m2	Intravenous
Subject	carboxyamidotriazole	Other / unclassified	50 mg/m2	Oral
Subject	carboxyamidotriazole	Other / unclassified	100 mg/m2	Oral
Subject	carboxyamidotriazole	Other / unclassified	250 mg/m2	Oral

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Summary

Timeline

Publications

Drugs

Indications